

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan hasil penelitian terhadap 88 pasien diabetes melitus tipe 2 di Depo Farmasi Rawat Jalan RSUD Haji Provinsi Jawa Timur, diperoleh kesimpulan sebagai berikut:

1. Mayoritas pasien termasuk dalam kategori risiko ASCVD sedang (47,7%) dan tinggi (36,4%), berdasarkan perhitungan menggunakan ASCVD Risk Estimator Plus, menunjukkan bahwa sebagian besar pasien memerlukan intervensi pencegahan primer yang intensif.
2. Sebanyak 96,5% pasien telah menerima terapi statin, namun seluruhnya menggunakan intensitas sedang, termasuk pada kelompok risiko tinggi yang seharusnya mendapatkan statin intensitas tinggi. Tidak ada pasien yang menerima terapi antiplatelet.

5.2 Saran

Perlu dilakukan penelitian lanjutan dikarenakan keterbatasan waktu dalam pengambilan subjek, sehingga disarankan penelitian lanjutan bisa menggunakan maksimal sampel subjek untuk memperoleh gambaran kondisi pasien yang lebih baik.

DAFTAR PUSTAKA

- Boutari, C., Rizos, C. V., Doulas, M., Liamis, G., Skoumas, I., Rallidis, L., Garoufi, A., Kolovou, G., Tziomalos, K., Skolidis, E., Kotsis, V., Sfikas, G., Lambadiari, V., Anagnostis, P., Biliannou, E., Anastasiou, G., Koutagiar, I., Kiouri, E., Attilakos, A. and Liberopoulos, E. 2023, Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH), *Pharmaceuticals*, **16(1)**: 6.
- Cetin, M., Maksutov, C., Isakulov, E. and Hosoglu Y. 2024, Effectiveness of SCORE2 and ASCVD Risk Scores in Combination with Aortic Arch Calcification on Chest Radiograph in Predicting Significant Coronary Artery Disease, *Angiology*, **75(8)**: 738.
- Choudhary, A., Rawat, U., Kumar, P. and Mittal, P. 2023, Pleotropic effects of statins: the dilemma of wider utilization of statin, *Egypt Heart J*, **75(1)**: 1.
- Duttagupta, S., Thachathodiyl, R., Rameshan, A., Venkatachalam, A., Georgy, S. Ts. D. and Menon, J. 2022, Effectiveness of Framingham and ASCVD Risk Scores in Predicting Coronary Artery Disease – A Comparative Study with Syntax Score, *J Assoc Physicians India*, **69(12)**: 11.
- Gourdy, P., Schiele, F., Halimi, J. M., Kownator, S., Hadjadj, S. and Valensi, P. 2023, Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines, *Frontiers in Cardiovascular Medicine*, **10**: 1227769.
- IDF, 2021, *IDF Diabetes Atlas*, 10th ed, International Diabetes Federation.
- Javed, Z., Haisum Maqsood, M., Yahya, T., Amin, Z., Acquah, I., Valero-Elizondo, J., Andrieni, J., Dubey, P., Jackson, R. K., Daffin, M. A., Cainzos-Achirica, M., Hyder, A. A. and Nasir, K. 2022, Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease, *Circulation: Cardiovascular Quality and Outcomes*, **15(1)**: 72.

- Katakami, N., 2018, Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus, *Journal of Atherosclerosis and Thrombosis*, **1(25)**: 28-29.
- Katzung, B.G. (ed). 2016, *Basic and Clinical Pharmacology*, 14th edn, McGraw-Hill Education, New York, USA.
- Kementerian Kesehatan RI, Formularium Nasional, 2023, Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan RI, Pedoman Nasional Pelayanan Kedokteran Tata Laksana Diabetes Melitus Tipe 2 Dewasa, 2020, Kementerian Kesehatan Republik Indonesia.
- Oesterle, A., Laufs, U., and Liao, J. K., 2017, Pleiotropic Effects of Statins on the Cardiovascular System, *Circulation Research*, **1(120)**: 235-237.
- PERKENI. 2021, *Pedoman Pengelolaan Dislipidemia di Indonesia*, PB. Perkeni.
- Soeatmadji, D. W., Rosandi, R., Saraswati, M. R., Sibarani, R. P. and Tarigan, W. O. 2023, Clinicodemographic Profile and Outcomes of Type 2 Diabetes Mellitus in the Indonesian Cohort of DISCOVER: A 3-Year Prospective Cohort Study, *Journal of the ASEAN Federation of Endocrine Societies*, **38(1)**: 69-70.
- Talha, I., Elkhoudri, N. and Hilali, A. 2024, Major Limitations of Cardiovascular Risk Scores, *Cardiovascular Therapeutics*, **1**: 1-2.
- Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., Piano, M. R., Rodriguez, F., Talbot, A. W., Taqueti, V. R., Thomas, R. J., van Diepen, S., Wiggins, B. and Williams, M. S. 2023, "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines", *Circulation*, **148**.

- Visseren, F., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J. M., Capodanno, D., Cosyns, B., Crawford, C. A., Davos, C. H., Desormais, I., Di Angelantonio, E., Duran, O. H. F., Halvorsen, S., Richard Hobbs, F. D., Hollander, M. and Mullabayeve, G. 2021, 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, *European Heart Journal*, **34(42)**: 3227
- Wong, N. D., Budoff, M. J., Ferdinand, K., Graham, I. M., Michos, E. D., Reddy, T., Shapiro, M. D. and Toth, P. P. 2022, Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement, *American Journal of Preventive Cardiology*, **10**: 100335.
- Yaputra, D. M., Wibowo, Y. I., Aditama, L., Brata, C. and Irawati, S. 2023, Faktor-Faktor yang Mempengaruhi Ketidaksesuaian Pemberian Statin pada First-user Statins di Apotek UBAYA Artikel Penelitian, *Media Pharmaceutical Indonesian*), **5(1)**: 1-6.